- |||||||||| lerodalcibep (LIB003) / LIB Therap
Enrollment closed, Trial completion date, Trial primary completion date: Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003 (clinicaltrials.gov) - Nov 15, 2019 P2b, N=32, Active, not recruiting, In 1 patient ADAs exceeded the level of assay sensitivity recommended by FDA with no impact on efficacy Enrolling by invitation --> Active, not recruiting | Trial completion date: Nov 2019 --> Mar 2020 | Trial primary completion date: Oct 2019 --> Mar 2020
- |||||||||| lerodalcibep (LIB003) / LIB Therap
Enrollment open: Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH (clinicaltrials.gov) - Nov 8, 2019 P3, N=70, Enrolling by invitation, Enrolling by invitation --> Active, not recruiting | Trial completion date: Nov 2019 --> Mar 2020 | Trial primary completion date: Oct 2019 --> Mar 2020 Not yet recruiting --> Enrolling by invitation
|